A first step towards the definitive treatment for diabetes with insulin-addiction
July 15, 2007 - Diabetes Type I is a conviction without a call for medical monitoring for life. Although salaries have become simpler and less in recent years, they still represent an obstacle, especially for children. The latest study published in the journal "Nature" by Dr. Constantin Polychronakos, director of the department of pediatric endocrinology at the MUHC, in collaboration with Dr. Hakon Hakonarson, director of the Centre for Applied Genomics at the Children's Hospital of Philadelphia (CHOP), is a hope that this situation evolve in the long term to the definitive treatment of this disease.
By using the innovative technology of DNA microchips, high-density, which allows testing 550,000 genes in a single analysis, and Dr. Polychronakos Dr Hakonarson have identified a new gene involved in diabetes type I. So far only 4 genes responsible for this disease were known, they are now 5. "We believe that there are around 15 genes involved in insulin-dependent diabetes, our study has shown that DNA microchips high density are an effective method and we hope to be able to identify all of these genes in a future close "says Dr. Polychronakos, also professor of pediatrics and human genetics at McGill University.
The causes of Type I diabetes are still unclear but it is estimated that 50% are the genetic predisposition. That's why validation of a new analytical method extremely powerful, and the identification of a new gene involved, are of great importance. Anyone who has just been discovered meets with the poetic name of "KIAA0350". Its precise function is not yet known, but it is mainly active in the immune system. This seems consistent as Type I diabetes is an autoimmune disease: the patient's immune system destroys its own cells in the pancreas, insulin-producing them by taking intruses for error.
Knowledge of these genes will move in parallel on two different therapeutic: prevention and treatment. The prevention because it will develop more effective tests for newborns likely to develop diabetes type I. The treatment because "we can draw very specific medicines targeting exactly the effects of the defective gene," predicts Dr. Hakonarson. Such treatments associated with a therapy for regeneration by stem cells, will allow patients to not feel any symptoms of diabetes.
"The prospect is still distant, but it is realistic, and this study is the first step," says Dr. Polychronakos.
This study was funded by the Juvenile Diabetes Research Foundation (JDRF), and Genome Canada.
About:
The Research Institute of the McGill University Health Center (MUHC) is a research center of world renown in the field of biomedical sciences and health care. Based in Montreal, Quebec, it is the basis for the MUHC research, teaching hospital affiliated with the Faculty of Medicine at McGill University. The institute has over 500 researchers, nearly 1000 graduate students and postdoctoral and more than 300 research laboratories devoted to a wide range of areas of research, clinical and basic science. The Research Institute is at the forefront of knowledge, innovation and technology. The Institute's research is closely linked to the clinical programs of the MUHC, which allows patients to benefit directly from scientific knowledge of the most advanced. For more information, see the address www.cusm.ca / research.
By using the innovative technology of DNA microchips, high-density, which allows testing 550,000 genes in a single analysis, and Dr. Polychronakos Dr Hakonarson have identified a new gene involved in diabetes type I. So far only 4 genes responsible for this disease were known, they are now 5. "We believe that there are around 15 genes involved in insulin-dependent diabetes, our study has shown that DNA microchips high density are an effective method and we hope to be able to identify all of these genes in a future close "says Dr. Polychronakos, also professor of pediatrics and human genetics at McGill University.
The causes of Type I diabetes are still unclear but it is estimated that 50% are the genetic predisposition. That's why validation of a new analytical method extremely powerful, and the identification of a new gene involved, are of great importance. Anyone who has just been discovered meets with the poetic name of "KIAA0350". Its precise function is not yet known, but it is mainly active in the immune system. This seems consistent as Type I diabetes is an autoimmune disease: the patient's immune system destroys its own cells in the pancreas, insulin-producing them by taking intruses for error.
Knowledge of these genes will move in parallel on two different therapeutic: prevention and treatment. The prevention because it will develop more effective tests for newborns likely to develop diabetes type I. The treatment because "we can draw very specific medicines targeting exactly the effects of the defective gene," predicts Dr. Hakonarson. Such treatments associated with a therapy for regeneration by stem cells, will allow patients to not feel any symptoms of diabetes.
"The prospect is still distant, but it is realistic, and this study is the first step," says Dr. Polychronakos.
This study was funded by the Juvenile Diabetes Research Foundation (JDRF), and Genome Canada.
About:
The Research Institute of the McGill University Health Center (MUHC) is a research center of world renown in the field of biomedical sciences and health care. Based in Montreal, Quebec, it is the basis for the MUHC research, teaching hospital affiliated with the Faculty of Medicine at McGill University. The institute has over 500 researchers, nearly 1000 graduate students and postdoctoral and more than 300 research laboratories devoted to a wide range of areas of research, clinical and basic science. The Research Institute is at the forefront of knowledge, innovation and technology. The Institute's research is closely linked to the clinical programs of the MUHC, which allows patients to benefit directly from scientific knowledge of the most advanced. For more information, see the address www.cusm.ca / research.
Categories:
0 komentar:
Posting Komentar